Adempas® (Riociguat): New Contraindication for Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias (PH-IIP)

Kadar pengguna: 3 / 5

bintang aktifbintang aktifbintang aktifBintang tidak aktifBintang tidak aktif

Date: 22 July 2016



Adempas® (riociguat) should not be used in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP). Riociguat is not approved for this indication. This recommendation follows the early termination of a phase II clinical trial called RISE-IIP study, which evaluated the efficacy and safety of riociguat in patients with symptomatic PH-IIP. Interim results of RISE-IIP showed an increased risk of mortality and serious adverse events among subjects receiving riociguat compared to those receiving placebo. The available data do not indicate a clinically significant benefit in these patients. The Malaysian Adempas® package insert will be updated to add a contraindication for PH-IIP to help ensure that riociguat is not used in these patients. If any patients with PH-IIP are being treated with riociguat, their treatment should be discontinued and their clinical status carefully monitored. Please refer to the Direct Healthcare Professional Communication (DHPC) for more details.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Profesor Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
  • Email:
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Jumaat 15 Oktober 2021, 15:58:04.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Choose Your Language

Menu Utama